Interleukin-33 and Behçet disease: Another cytokine among others

Human Immunology

Volumn 76, Issue 5, 2015, Pages 301-306

  Hamzaoui, Kamel ^a   Bouali, Eya ^a   Hamzaoui, Agnès ^a,b  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^b ABDERRAHMAN MAMI HOSPITAL   (Tunisia)

Author keywords

Alarmin; Beh et disease; IL 33; Inflammation; Innate and adaptive immunity; ST2

Indexed keywords

INTERLEUKIN 33; AUTACOID; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1;

BEHCET DISEASE; CELL DEATH; CENTRAL NERVOUS SYSTEM; ENDOTHELIUM CELL; EPITHELIUM CELL; ERYTHEMA NODOSUM; IMMUNE SYSTEM; INFLAMMATORY CELL; INNATE IMMUNITY; PATHOGENESIS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN DEFECT; STRESS; TISSUE INJURY; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; HUMAN; IMMUNOLOGY; METABOLISM;

ANIMALS; BEHCET SYNDROME; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-33; RECEPTORS, CELL SURFACE;

EID: 84928584777     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2015.03.011     Document Type: Review

References (44)

1. Sugita S., Kawazoe Y., Imai A., Kawaguchi T., Horie S., Keino H., et al. Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet's disease. J. Immunol. 2013, 190(11):5799-5808.
2. Shimizu J., Takai K., Fujiwara N., Arimitsu N., Ueda Y., Wakisaka S., et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behçet's disease. Clin. Exp. Immunol. 2012, 168(1):68-74.
3. Hamzaoui K. Th17 cells in Behçet's disease: a new immunoregulatory axis. Clin Exp Rheumatol 2011, 29(4 Suppl 67):S71-S76.
4. Hamzaoui K., Borhani Haghighi A., Ghorbel I.B., Houman H. RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet's disease. J. Neuroimmunol. 2011, 233(1-2):249-253.
5. Hamzaoui K., Hamzaoui A. Immunological responses in patients with Behçet's disease: advances in understanding. Expert Rev. Ophthalmol. 2012, 7(3):261-270.
6. Hamzaoui K., Hamza M., Ayed K. Production of TNF-alpha and IL-1 in active Behçet's disease. J. Rheumatol. 1990, 17(10):1428-1429.
7. Hamzaoui K., Hamzaoui A., Guemira F., Bessioud M., Hamza M., Ayed K. Cytokine profile in Behçet's disease patients. relationship with disease activity. Scand. J. Rheumatol. 2002, 31(4):205-210.
8. Htoon J., Nadig A., Hughes T., Yavuz S., Direskeneli H., Saruhan-Direskeneli G., et al. IL18 polymorphism is associated with Behçet's disease but not lupus in patients from Turkey. J. Rheumatol. 2011, 38(5):962-963.
9. Musabak U., Pay S., Erdem H., Simsek I., Pekel A., Dinc A., et al. Serum interleukin-18 levels in patients with Behçet's disease. Is its expression associated with disease activity or clinical presentations?. Rheumatol. Int. 2006, 26(6):545-550.
10. Barksby H.E., Lea S.R., Preshaw P.M., Taylor A.Y.J.J. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin. Exp. Immunol. 2007, 149:217-225.
11. Zou J., Guan J.L. Interleukin-1-related genes polymorphisms in Behçet disease: a meta-analysis. Mod. Rheumatol. 2014, 24(2):321-326.
12. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
13. Carriere V., Roussel L., Ortega N., Lacorre D.A., Americh L., Aguilar L., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:282-287.
14. Oboki K., Ohno T., Kajiwara N., Arae K., Morita H., Ishii A., et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18581-18586.
15. Chackerian A.A., Oldham E.R., Murphy E.E., Schmitz J., Pflanz S., Kastelein R.A. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 2007, 179:2551-2555.
16. Palmer G., Lipsky B.P., Smithgall M.D., Meininger D., Siu S., Talabot-Ayer D., et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008, 42:358-364.
17. Hayakawa H., Hayakawa M., Kume A., Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 2007, 282:26369-26380.
18. Matta B.M., Lott J.M., Mathews L.R., Liu Q., Rosborough B.R., Blazar B.R., et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J. Immunol. 2014, 193(8):4010-4020.
19. Bulek K., Swaidani S., Qin J., Lu Y., Gulen M.F., Herjan T., et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J. Immunol. 2009, 182:2601-2609.
20. Kopach P., Lockatell V., Pickering E.M., Haskell R.E., Anderson R.D., Hasday J.D., Todd N.W., Luzina I.G., Atamas S.P. IFN-γ directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism. J. Biol. Chem. 2014, 289(17):11829-11843.
21. Mu R., Huang H.Q., Li Y.H., Li C., Ye H., Li Z.G. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J. Rheumatol. 2010, 37:2006-2013.
22. Xu W.D., Zhang M., Zhang Y.J., Ye D.Q. IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy. Hum. Immunol. 2013, 74(9):1057-1060.
23. Yang Z., Liang Y., Xi W., Li C., Zhong R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin. Exp. Med. 2011, 11:75-80.
24. Kim D.J., Baek S.Y., Park M.K., Park K.S., Lee J.H., Park S.H., et al. Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease. J. Korean Med. Sci. 2013, 28(8):1145-1153.
25. Hamzaoui K., Kaabachi W., Fazaa B., Zakraoui L., Mili-Boussen I., Haj-Sassi F. Serum IL-33 levels and skin mRNA expression in Behçet's disease. Clin. Exp. Rheumatol. 2013, 31(3 Suppl 77):6-14.
26. Koca S.S., Kara M., Deniz F., Ozgen M., Demir C.F., Ilhan N., et al. Serum IL-33 level and IL-33 gene polymorphisms in Behçet's disease. Rheumatol. Int. 2014.
27. Barbour M., Allan D., Xu H., Pei C., Chen M., Niedbala W., Fukada S.Y., Besnard A.G., Alves-Filho J.C., Tong X., Forrester J.V., Liew F.Y., Jiang H.R. IL-33 attenuates the development of experimental autoimmune uveitis. Eur. J. Immunol. 2014, 44(11):3320-3329.
28. Todaro M., Zerilli M., Triolo G., Iovino F., Patti M., Accardo-Palumbo A., et al. NF-kappaB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum. 2005, 52:2179-2191.
29. Ohno T., Oboki K., Morita H., Kajiwara N., Arae K., Tanaka S., et al. Paracrine IL-33 stimulation enhances lipopolysaccharide-mediated macrophage activation. PLoS One 2011, 6:e18404.
30. Melikoglu M., Uysal S., Krueger J.G., Kaplan G., Gogus F., Yazici H., et al. Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J. Immunol. 2006, 177(9):6415-6421.
31. Pushparaj P.N., Tay H.K., H'Ng S.C., Pitman N., Xu D., McKenzie A., et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9773-9778.
32. Hueber A.J., Alves-Filho J.C., Asquith D.L., Michels C., Millar N.L., Reilly J.H., et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur. J. Immunol. 2011, 41(8):2229-2237.
33. Yanaba K., Yoshizaki A., Asano Y., Kadono T., Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin. Rheumatol. 2011, 30:825-830.
34. Sponheim J., Pollheimer J., Olsen T., Balogh J., Hammarström C., Loos T., et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 2010, 177:2804-2815.
35. Verri W.A., Guerrero A.T., Fukada S.Y., Valerio D.A., Cunha T.M., Xu D., et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2723-2728.
36. Saruhan-Direskeneli G., Yentür S.P., Akman-Demir G., Işik N., Serdaroğlu P. Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases. J. Neuroimmunol. 2003, 145:127-134.
37. Hamzaoui K., Borhani-Haghighi A., Kaabachi W., Hamzaoui A. Increased interleukin 33 in patients with neuro-Behcet's disease: correlation with MCP-1 and IP-10 chemokines. Cell. Mol. Immunol. 2014, 11(6):613-616.
38. Hudson C.A., Christophi G.P., Gruber R.C., Wilmore J.R., Lawrence D.A., Massa P.T. Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 2008, 84:631-643.
39. Puneet P., Moochhala S., Bhatia M. Chemokines in acute respiratory distress syndrome. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288:L3-L15.
40. Ali S., Mohs A., Thomas M., Klare J., Ross R., Schmitz M.L., et al. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J. Immunol. 2011, 187(4):1609-1616.
41. Li M., Li Y., Liu X., Gao X., Wang Y. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J. Neuroimmunol. 2012, 247:25-31.
42. Yasuoka S., Kawanokuchi J., Parajuli B., Jin S., Doi Y., Noda M., et al. Production and functions of IL-33 in the central nervous system. Brain Res. 2011, 1385:8-17.
43. Christophi G.P., Gruber R.C., Panos M., Christophi R.L., Jubelt B., Massa P.T. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin. Immunol. 2012, 142:308-319.
44. Pomeshchik Y., Kidin I., Korhonen P., Savchenko E., Wojciechowski S., Kanninen, et al. Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav. Immun. 2015, 44:68-81.